title: Which calcineurin inhibitor is preferred in renal transplantation: tacrolimus or cyclosporine?
abstract: Cyclosporine and tacrolimus are potent inhibitors of the calcineurin-dependent cytokine synthesis in activated lymphocytes. In renal transplant patients tacrolimus is more powerful in preventing severe and refractory rejections, even when compared with the new cyclosporine microemulsion formulation. Both drugs are equally nephrotoxic, but tacrolimus induces less hypertension and less pronounced hyperlipidaemia. Especially in some categories of patients, a higher incidence of de-novo diabetes mellitus is seen with tacrolimus therapy.
authors.affiliation: University Hospital Gasthuisberg, Leuven, Belgium. yves.vanrenterghem@uz.kuleuven.ac.be
authors.forename: Y F
authors.initials: YF
authors.lastname: Vanrenterghem
mesh_terms: D001161:Arteriosclerosis / Q000139:chemically induced; D065095:Calcineurin Inhibitors; D016572:Cyclosporine / Q000627:therapeutic use*; D003920:Diabetes Mellitus / Q000139:chemically induced; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007674:Kidney Diseases / Q000139:chemically induced; D016030:Kidney Transplantation; D016559:Tacrolimus / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D016559:Tacrolimus